ADAR1 Capital Keeps Buying InMed Shares, Gaining 17% Stake Amid Low‑Price Dip

ADAR1 Capital’s Fresh Injection of Cash into InMed

The latest Form 4 filing shows ADAR1 Capital Management, LLC purchasing 5,601 shares of InMed Pharmaceuticals on 6 October 2026 at $1.33 per share – the same price that closed the market. The purchase is part of a steady stream of buys that have seen the fund’s stake rise from roughly 830,000 shares in mid‑September to nearly 946,000 shares today, giving ADAR1 a de‑facto 17 % holding. The transaction itself is small relative to the fund’s overall position, but its timing and consistency raise several questions for investors.

What the Current Purchase Says About Confidence

ADAR1’s recent buying spree comes amid a broader decline in InMed’s stock price, which has fallen 1.5 % in the week and 37 % on the year. Despite this, the fund continues to add shares at a stable price level. This suggests a “buy‑the‑dip” mentality: the fund sees the current valuation as an attractive entry point for long‑term exposure, likely anticipating a rebound in the company’s cannabinoid pipeline or a strategic partnership that could unlock value. The transaction’s low sentiment score and modest buzz indicate that the market has not yet reacted strongly, which may create a window for other investors to follow the fund’s lead.

Implications for InMed’s Future and Shareholders

The incremental share increase strengthens ADAR1’s voting power—though the fund has stated that it holds no controlling interest. In practice, a 17 % stake can influence board discussions, especially in a biotech firm where a few large shareholders can sway strategic decisions such as drug development focus, licensing deals, or capital allocation. The fund’s continued accumulation may also signal a belief that InMed’s proprietary platform will deliver clinical successes, potentially driving future price appreciation. For shareholders, this could mean a tighter concentration of ownership that may lead to more disciplined governance and a clearer path toward commercialization.

ADAR1 Capital Management: A Profile of the Investor

ADAR1 Capital is an investment firm that has steadily built a sizable position in InMed over the past six months. Its purchase pattern is characterized by:

The fund’s acquisitions have been relatively large (up to 54,000 shares in a single day) and executed at a narrow price range ($1.29–$1.33), indicating a disciplined, data‑driven approach rather than opportunistic buying. ADAR1’s consistent stake growth suggests a long‑term view, likely tied to the company’s research milestones rather than short‑term market swings. The firm’s 13G/A filing confirms that it holds no controlling interest, reinforcing the interpretation that its focus is on value creation through a substantial minority holding.

What Investors Should Watch

1. Pipeline Milestones – InMed’s cannabis‑based therapies are still in pre‑clinical stages; any positive data or partnership announcements could trigger a rally.
2. Capital Structure – As ADAR1’s stake grows, watch for changes in voting rights, proxy materials, and any indications of board influence.
3. Market Sentiment – The current low buzz and neutral sentiment suggest that price reactions may lag; keep an eye on social‑media chatter for shifts.
4. Fund Activity – ADAR1’s continued buying, despite a declining share price, may signal an upcoming upside; however, any large sell‑offs could quickly erode the fund’s influence.

In summary, ADAR1 Capital’s latest purchase is a modest yet telling addition to a growing stake that could enhance its influence over InMed’s strategic direction. For investors, the move underscores a bullish stance on the company’s long‑term prospects while highlighting potential governance shifts that could shape the stock’s trajectory.